Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 filgotinib program in active axial spondyloarthritis
2022-501354-10-01Phase 3Authorised
- Sponsor
- Alfasigma
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Filgotinib 200 mg with Placebo (2 arms). Primary endpoint: ASAS40 response at week 16. Planned start May 2023; status: authorised.
02
Drugs
filgotinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2022-501354-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501354-10-01.